• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

ACC ’18 Roundup: OrbusNeich Combo drug-eluting stent succeeds in registries

March 12, 2018 By Sarah Faulkner

OrbusNeichOrbusNeich touted pooled data from two registries evaluating its dual-therapy stent this week at the annual meeting of the American College of Cardiology.

The Combo stent was implanted in more than 3,600 all-comer patients and followed by researchers for one year. The registries found that the device was safe and effective after one year, featuring a low stent thrombosis rate of 0.8% and a 3.9% rate of major cardiac event at one year.

Researchers presenting the data at ACC ’18 noted that these results, while promising, need to be further examined in a randomized, controlled clinical trial and compared to other drug-eluting stents, according to reports from MedScape.

OrbusNeich’s Combo stent, which combines sirolimus and a layer of antibodies designed to capture endothelial progenitor cells, won CE Mark clearance in the European Union in 2013.

The study presented at ACC ’18 combined data from 1,000 patients in the Remedee registry who received the device between 2013 and 2014, as well as 2,624 patients in the Mascot registry who were implanted with the device between 2014 and 2016.

Researchers reported observing target lesion failure in 3.9% of patients. Of the 140 patients who experienced TLF, 1.6% died from cardiac causes, 1.2% had target vessel MI and 2.2% had target lesion revascularization, MedScape reported.

At last year’s Transcatheter Cardiovascular Therapeutics meeting, OrbusNeich and Medtronic presented work comparing shortened durations of dual anti-platelet therapy with the standard 1-year regimen in patients treated with a drug-eluting stent.

In OrbusNeich’s study, investigators hypothesized that they could reduce the duration of DAPT by using the company’s Combo dual therapy stent.

The study enrolled 1,496 patients with acute coronary syndrome and treated them with the Combo dual therapy stent and either three months or 12 months of DAPT. The trial’s primary endpoint was a composite of all-cause mortality, myocardial infarction, stent thrombosis, stroke, target-vessel revascularization and bleeding at 12 months.

There was no difference in the primary endpoint between three and 12 months DAPT, the company reported, and bleeding rates were similar among both treatment groups.

Get the rest of the ACC ’18 Roundup on our sister site, MassDevice.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: OrbusNeich

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS